Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: JOEBT1 who wrote (1147)	5/30/2000 10:50:00 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 52153

JOEBT1, I never done in-dept analysis of IMGN, so may be of little help. IMGN cough my ayes with IND (SKB) and recent deal with DNA (herceptin). However, I am bit skeptical about tumor activated pro-drug technology. I agree that bounding toxic agent with selective and specific mAb will increase drug efficiency (increased therapeutic index), but will not claim that this combination isn't toxic (systemic therapy). Anyway, it will be interesting to follow SKB PI trial and what type of results they will report. Regards, Miljenko